HIV (antiretroviral therapy) ⭐

hiv · high-yield

← back to Infectious Diseases

Summary

The IAS-USA 2024 panel updates recommendations for antiretroviral therapy and HIV prevention in adults. ART is recommended for all individuals with HIV, with bictegravir- or dolutegravir-based InSTI regimens plus 2 NRTIs (TXF/XTC) as preferred initial therapy; DTG/3TC is the only recommended 2-drug initial option. New elements include broader statin use for ASCVD primary prevention (per REPRIEVE), doxycycline PEP for bacterial STI prevention, long-acting cabotegravir for PrEP, and integrated management of substance use disorders, weight gain, and cardiometabolic comorbidities.

Current guideline: IAS-USA 2024 Recommendations · download Anki sub-deck

Versions